Boosting Vaccine Research : The 16-Year Journey of TRANSVAC Vaccine Infrastructure
Martin, William (European Vaccine Initiative (EVI))
Luís, Catarina (European Vaccine Initiative)
Jungbluth, Stefan (European Vaccine Initiative)
Slezak, Monika (European Vaccine Initiative)
Verreck, Frank A.W. (Biomedical Primate Research Centre)
Spiegel, Holger (Fraunhofer Institute for Molecular Biology and Applied Ecology IME)
Guzman, Carlos A. (Helmholtz Centre for Infection Research)
Roldão, António (iBET-Instituto de Biologia Experimental e Tecnológica)
Carrondo, Manuel J.T. (iBET-Instituto de Biologia Experimental e Tecnológica)
Van der Ley, Peter (Intravacc)
Segalés Coma, Joaquim (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals)
Dockrell, Hazel M. (London School of Hygiene and Tropical Medicine)
Ho, Mei Mei (Medicines and Healthcare Products Regulatory Agency)
Pedersen, Gabriel K. (Statens Serum Institut)
Lawrenz, Maria (Vaccine Formulation Institute)
Olesen, Ole F. (European Vaccine Initiative)

Data:	2024
Resum:	TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market.
Ajuts:	European Commission 730964
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Research and development ; Research infrastructure ; Vaccine ; SDG 3 - Good Health and Well-being
Publicat a:	Vaccines (Basel), Vol. 12 Núm. 12 (2024) , p. 1446, ISSN 2076-393X

DOI: 10.3390/vaccines12121446
PMID: 39772106

18 p, 2.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Centre de Recerca en Sanitat Animal (CReSA-IRTA)
Articles > Articles de recerca
Articles > Articles publicats